Posted by Michael Wonder on 26 Jan 2024
CHMP issues negative opinion for renewal of conditional marketing authorisation for Translarna (ataluren) following re-examination procedure
25 January 2024 - PTC Therapeutics announced today that the CHMP of the EMA issued a negative opinion following the re-examination procedure for the conditional marketing authorisation of Translarna (ataluren).
Per European regulations, the European Commission has 67 days to adopt the opinion.
